HomePeptides › Selank

Selank

TP-7

Tier 3 · Limited Human Data
Class
Tuftsin analog
Molecular target
GABAergic and monoaminergic modulation; enkephalinase inhibition
Sequence / structure
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Evidence tier
Tier 3 — Limited Human Data
Category
Neuropeptides
Emergency card
Signs something is wrong

Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.

What to do now

Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.

When it is an emergency

Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.

Any injection — every time

Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.

This is not permission or instruction to use this compound. It is harm-reduction information for someone who has already decided to, so that a bad reaction is recognised and treated. When in doubt, get help — embarrassment is survivable.

Biology & mechanism

A synthetic analog of the immunomodulatory tetrapeptide tuftsin, stabilised with a Pro-Gly-Pro extension. Proposed anxiolytic activity via modulation of GABA-A receptor expression, inhibition of enkephalin degradation, and effects on serotonergic tone — reportedly without the sedation, dependence, or withdrawal associated with benzodiazepines.

What the research actually shows

As with Semax: developed and studied in Russia, registered there for anxiety disorders, with a trial literature that is largely Russian-language and not independently replicated or reviewed by Western regulators.

Regulatory status

Not FDA-approved. Registered as a medicine in Russia. Not lawfully marketed for human use in the US.

Safety signals

Reported tolerability is favourable in the Russian literature; independent verification is lacking. Long-term data unavailable.

Clinical trial dosing — what the studies actually used

A registered medicine in Russia, given intranasally per its national registration. Not FDA-reviewed; trial literature not independently validated.

Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.

We report study doses, not protocols

Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.

References & further reading

Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.

Important notice Forge Bioenergy publishes scientific reference information only. Nothing on this site is medical advice, a therapeutic claim, or a recommendation to use any substance in humans. Many peptides described here are not approved by the FDA for any use, and several are approved only for narrow indications under prescription. We do not publish dosing, administration, or usage protocols. Consult a licensed physician before making any medical decision.